Ultragenyx Rare Disease Voucher Sales Secure $413M for More Potential Pipeline Building
Ultragenyx Pharmaceutical sold two priority review vouchers, each from an FDA approval of a gene therapy. Both therapies came from business deals and proceeds from the voucher sales put Ultragenyx in a better financial position to pursue yet another deal for a rare disease asset.
Healthleap Raises $38M to Expand AI Screening for Overlooked Conditions in Hospitalized Patients
Healthleap, a clinical AI platform that works within the EHR to screen hospitalized patients for conditions that might otherwise go undiagnosed, is supporting hospitals in finding at-risk patients sooner.
Why Agentic AI Works in Hospitals When You Strip It Down
Many hospitals are now trying to use AI to automate processes and free up staff time, running simultaneous pilots to perform as many tasks as possible. This quickly leads to pilot sprawl — a state where organizations can no longer even say which agents are still in active use.
Happy Health’s Cuffless BP Device Wins FDA Clearance
Happy Health has received FDA clearance for its wearable ring, which continuously measures blood pressure without a cuff or external calibration.
Roche Puts Up $100M to Pursue Promising But Competitive New Target in Obesity
Roche gains global rights to a Rona Therapeutics RNA interference drug designed to target ALK7, a genetically validated target for obesity and other metabolic indications. The growing field of companies pursuing ALK7 includes GSK and Arrowhead Pharmaceuticals.